Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Q4 2021 vs. Q3 2021
How the institutions holding Genmab A/S changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 213 | 3 | 212 | +2 |
| Shares | 42.8M | 2.66K | 39.8M | −2.99M (−7.0%) |
| Value | $1.89B | $115.0K | $1.58B | −$314.9M (−16.6%) |
3 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (31)
Institutions that held Genmab A/S at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (29)
Institutions that held Genmab A/S at the end of Q3 2021 and filed for Q4 2021 without it.
Not filed for Q4 2021 yet (3)
Institutions that held Genmab A/S at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| BBVA USA | 1,677 | $73.0K |
| Berman Capital Advisors, LLC | 894 | $38.0K |
| Sonora Investment Management, LLC | 91 | $4.00K |